Dennis Purcell has served as the Senior Managing Director of Aisling Capital since February 2000. Prior to that, Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&O (formerly Hambrecht & Quist, “H&Q”) for over 5 years, and served on the Executive Committee of Hambrecht & Quist. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities from 1995 through 1998. Purcell has also often been cited as one of the sectors leaders. He was honored in the “Biotech Hall of Fame” by Genetic Engineering News in June 1998 and named to the Biotechnology All-Stars list by Forbes ASAP in May 1999.

Purcell serves as a director of Auxilium Pharmaceuticals, Inc., Valentis, Inc., Xanodyne Pharmaceuticals, Inc. and Bridge Pharmaceuticals, Inc. He is also a member of the Board of Directors of the Biotechnology Industry Organization (BIO) Emerging Companies section and the Irvington Institute. Purcell received a B.S. in Economics and Accounting from the University of Delaware and an M.B.A. from Harvard University. He is a second-generation Irish American with family from Tyrone and Kilkenny. He is married with four children.